Clinical Chemistry Instruments and Reagents Under Scrutiny at the 2015 AACC Annual Meeting
|
By LabMedica International staff writers Posted on 27 Jul 2015 |

Image: The Altair 240 clinical chemistry analyzer (Photo courtesy of EKF Diagnostics).

Image: The Stanbio Chemistry GSP LiquiColor Assay analyzer (Photo courtesy of EKF Diagnostics).
Clinical chemistry, both instrumentation and reagents, was the focus of presentations at booth 1018 at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).
EKF Diagnostics (Cardiff, United Kingdom), a global in vitro diagnostics company, took advantage of the AACC Annual Meeting to launch the Altair 240 clinical chemistry analyzer.
This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. EKF believes that the new Altair 240 clinical chemistry analyzer fulfills an international market need for a fully automated bench-top platform supported by the reliable Stanbio Chemistry (Boerne, TX, USA) reagent menu.
“We listened to the needs of our customers and designed the Altair 240 to be easy to learn, operate, and maintain,” said Albert Blanco, business unit director at EKF Diagnostics. “Because it runs on Windows 7, operators can easily navigate its intuitive, touch screen menu. Features such as the capability to use bar coded, primary sample tubes, auto-rerun, auto-dilution and STAT interruption—all function to maximize the system’s overall efficiency.”
EKF will also use the AACC Annual Meeting venue to discuss the latest additions to its Stanbio clinical chemistry range. This range includes a large selection of clinical chemistry assays, controls, and calibrators, which are fully compatible with most major brand open channel chemistry analyzers.
A notable addition to the reagent menu is the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor test; a new diabetes biomarker test that provides a two to three week indicator of average blood glucose. The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.
Other instruments to be highlighted at the AACC Annual Meeting include the DiaSpect and HemoPoint H2. DiaSpect is a hand held device touted as being the world’s fastest hemoglobin measurement system. The instrument is described as offering laboratory quality performance for anemia screening in all climatic conditions in less than two seconds. The HemoPoint H2 stores over 4000 patient results and is designed for use in blood banks, clinics, and hospitals. This instrument provides immediate and simultaneous high quality results for both hemoglobin and hematocrit.
Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
EKF Diagnostics
Stanbio Chemistry
EKF Diagnostics (Cardiff, United Kingdom), a global in vitro diagnostics company, took advantage of the AACC Annual Meeting to launch the Altair 240 clinical chemistry analyzer.
This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. EKF believes that the new Altair 240 clinical chemistry analyzer fulfills an international market need for a fully automated bench-top platform supported by the reliable Stanbio Chemistry (Boerne, TX, USA) reagent menu.
“We listened to the needs of our customers and designed the Altair 240 to be easy to learn, operate, and maintain,” said Albert Blanco, business unit director at EKF Diagnostics. “Because it runs on Windows 7, operators can easily navigate its intuitive, touch screen menu. Features such as the capability to use bar coded, primary sample tubes, auto-rerun, auto-dilution and STAT interruption—all function to maximize the system’s overall efficiency.”
EKF will also use the AACC Annual Meeting venue to discuss the latest additions to its Stanbio clinical chemistry range. This range includes a large selection of clinical chemistry assays, controls, and calibrators, which are fully compatible with most major brand open channel chemistry analyzers.
A notable addition to the reagent menu is the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor test; a new diabetes biomarker test that provides a two to three week indicator of average blood glucose. The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.
Other instruments to be highlighted at the AACC Annual Meeting include the DiaSpect and HemoPoint H2. DiaSpect is a hand held device touted as being the world’s fastest hemoglobin measurement system. The instrument is described as offering laboratory quality performance for anemia screening in all climatic conditions in less than two seconds. The HemoPoint H2 stores over 4000 patient results and is designed for use in blood banks, clinics, and hospitals. This instrument provides immediate and simultaneous high quality results for both hemoglobin and hematocrit.
Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
EKF Diagnostics
Stanbio Chemistry
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more








